ZVRA (Zevra Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ZVRA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-17 | Rahsaan Thompson | Chief Legal & Compliance | Sell | — | — |
| 2026-08-12 | Corey Michael Watton | Director | MIXED | — | — |
| 2026-06-23 | Rahsaan Thompson | Chief Legal & Compliance | MIXED | — | — |
| 2026-06-18 | TAMARA A FAVORITO | Director | A | — | — |
| 2026-06-18 | Alicia Secor | Director | A | — | — |
| 2026-06-18 | Corey Michael Watton | Director | A | — | — |
| 2026-06-18 | Thomas Anderson | Director | A | — | — |
| 2026-06-18 | Douglas W Calder | Director | A | — | — |
| 2026-06-18 | Alvin Shih | Director | A | — | — |
| 2026-05-29 | Timothy J. Sangiovanni | SVP, Finance & Corp Controller | A | — | — |
| 2026-05-13 | Rahsaan Thompson | Chief Legal & Compliance | Sell | — | — |
| 2026-03-26 | John B Bode | Director | M | — | — |
| 2026-03-19 | Justin A Renz | CFO | A | — | — |
| 2026-02-10 | Neil F. McFarlane | President and CEO | MIXED | — | — |
| 2026-02-04 | Joshua Schafer | CCO | Sell | — | — |
| 2026-02-04 | Timothy J. Sangiovanni | SVP, Finance & Corp Controller | Sell | — | — |
| 2026-02-02 | Timothy J. Sangiovanni | SVP, Finance & Corp Controller | MIXED | — | — |
| 2026-02-02 | Neil F. McFarlane | President and CEO | MIXED | — | — |
| 2026-02-02 | Adrian W Quartel | Chief Medical Officer | MIXED | — | — |
| 2026-02-02 | Rahsaan Thompson | Chief Legal & Compliance | MIXED | — | — |
| 2026-02-02 | Joshua Schafer | CCO | MIXED | — | — |
| 2026-01-07 | R. LaDuane Clifton | — | MIXED | — | — |
| 2025-12-09 | Alicia Secor | Director | A | — | — |
| 2025-10-10 | Neil F. McFarlane | President and CEO | MIXED | — | — |
| 2025-09-16 | TAMARA A FAVORITO | Director | Buy | — | — |
| 2025-09-15 | Alvin Shih | Director | Buy | — | — |
| 2025-08-20 | John B Bode | Director | Buy | — | — |
| 2025-06-30 | Rahsaan Thompson | Chief Legal & Compliance | Sell | — | — |
| 2025-06-24 | Rahsaan Thompson | Chief Legal & Compliance | M | — | — |
| 2025-05-30 | Alvin Shih | Director | A | — | — |
| 2025-05-30 | TAMARA A FAVORITO | Director | A | — | — |
| 2025-05-30 | WENDY L DIXON | Director | A | — | — |
| 2025-05-30 | Douglas W Calder | Director | A | — | — |
| 2025-05-30 | Corey Michael Watton | Director | A | — | — |
| 2025-05-30 | John B Bode | Director | A | — | — |
| 2025-05-30 | Thomas Anderson | Director | A | — | — |
| 2025-03-31 | Corey Michael Watton | Director | Buy | — | — |
| 2025-03-27 | Adrian W Quartel | Chief Medical Officer | A | — | — |
| 2025-03-21 | John B Bode | Director | Buy | — | — |
| 2025-02-14 | Timothy J. Sangiovanni | SVP, Finance & Corp Controller | Sell | — | — |
| 2025-02-14 | R. LaDuane Clifton | CFO & Treasurer | Sell | — | — |
| 2025-02-14 | Joshua Schafer | CCO & EVP, Bus. Development | Sell | — | — |
| 2025-02-14 | Neil F. McFarlane | President and CEO | Sell | — | — |
| 2025-02-10 | Neil F. McFarlane | President and CEO | A | — | — |
| 2025-02-03 | Timothy J. Sangiovanni | SVP, Finance & Corp Controller | M | — | — |
| 2025-02-03 | Neil F. McFarlane | President and CEO | M | — | — |
| 2025-02-03 | R. LaDuane Clifton | CFO & Treasurer | M | — | — |
| 2025-02-03 | Rahsaan Thompson | Chief Legal & Compliance | A | — | — |
| 2025-02-03 | Joshua Schafer | CCO & EVP, Bus. Development | M | — | — |
| 2024-10-16 | Corey Michael Watton | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 401,850 | — |
| — | CFO & Treasurer | 143,515 | — |
| — | Director | 123,400 | — |
| — | CCO | 62,278 | — |
| — | Chief Legal & Compliance | 37,569 | — |
| — | Chief Executive Officer | 29,973 | — |
| — | SVP, Finance & Corp Controller | 29,590 | — |
| — | Director | 20,000 | — |
| — | Director | 20,000 | — |
| — | Director | 18,569 | — |
| — | Chief Medical Officer | 14,256 | — |
| — | Director | 14,100 | — |
| — | Director | 10,835 | — |
| — | Director | 3,894 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ZVRA quote page; the site-wide leaderboard is on the insider transactions hub.